Opinion

Video

Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis

Author(s):

Christopher G. Bunick, MD, PhD,Lindsay S. Ackerman, MD, FAAD

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors.

Video content above is prompted by the following:

  • What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment?
Related Videos
3 experts are featured in this series.
Related Content
Study Highlights New Data on Probiotics as Food Allergy Treatment for Children
January 17th 2025

Study Highlights New Data on Probiotics as Food Allergy Treatment for Children

Tim Smith
Skin of Color Savvy: News Update—SOCS Awards, My Best Winter Skin, & TORPEDO Program
January 15th 2025

Skin of Color Savvy: News Update—SOCS Awards, My Best Winter Skin, & TORPEDO Program

Robert Brodell, MD
AI Demonstrates Diagnostic Accuracy for Conditions Such as Psoriasis, Eczema
January 16th 2025

AI Demonstrates Diagnostic Accuracy for Conditions Such as Psoriasis, Eczema

Tim Smith
Advances in Pediatric Eczema Highlight 2022
December 21st 2022

Advances in Pediatric Eczema Highlight 2022

Kevin Kunzmann
Study Highlights Findings on Chronic Hand Eczema from Skin Tape Stripping
January 10th 2025

Study Highlights Findings on Chronic Hand Eczema from Skin Tape Stripping

Tim Smith
New Phase 2a Findings Released on IMG-007 Treatment of Atopic Dermatitis
January 9th 2025

New Phase 2a Findings Released on IMG-007 Treatment of Atopic Dermatitis

Tim Smith
© 2025 MJH Life Sciences

All rights reserved.